Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Hepatocellular × ribociclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 103 Neoplasms 11 Neoplasm Metastasis 11 Glioma 8 Ovarian Neoplasms 6 Melanoma 6 Glioblastoma 6 Squamous Cell Carcinoma of Head and Neck 5 Liposarcoma 5 Carcinoma, Non-Small-Cell Lung 5 Sarcoma 4 Recurrence 4 Medulloblastoma 4 Endometrial Neoplasms 4 Diffuse Intrinsic Pontine Glioma 4 Colorectal Neoplasms 4 Breast Diseases 4 Brain Neoplasms 4 Neuroblastoma 3 Neoplasms by Site 3 Lymphoma 3 Fallopian Tube Neoplasms 3 Carcinoma, Ovarian Epithelial 3 Breast Neoplasms, Male 3 Astrocytoma 3 Triple Negative Breast Neoplasms 2 Rhabdoid Tumor 2 Prostatic Neoplasms 2 Neoplasms, Germ Cell and Embryonal 2 Multiple Endocrine Neoplasia Type 1 2

Interventions

Sorafenib 222 lenvatinib 145 Bevacizumab 129 Nivolumab 86 atezolizumab 79 pembrolizumab 75 Radiosurgery 71 durvalumab 63 Oxaliplatin 60 sintilimab 59 Fluorouracil 56 Doxorubicin 47 tislelizumab 45 apatinib 44 Radiofrequency Ablation 44 Hepatectomy 42 Leucovorin 41 camrelizumab 40 Radiotherapy 40 tremelimumab 37 Magnetic Resonance Spectroscopy 36 regorafenib 34 Capecitabine 30 Immune Checkpoint Inhibitors 29 Folfox protocol 28 Cisplatin 28 Gemcitabine 26 Cyclophosphamide 26 cabozantinib 25 Ipilimumab 25

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02524119 2021-02-01

LEE001

University of Texas Southwestern Medical Center

Phase 2 Terminated

5 enrolled 9 charts

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡